Literature DB >> 26135247

Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.

Leopold Kong1, Rameshwar U Kadam1, Erick Giang2, Tinashe B Ruwona2, Travis Nieusma1, Jeffrey C Culhane3, Robyn L Stanfield1, Philip E Dawson3, Ian A Wilson4, Mansun Law5.   

Abstract

Hepatitis C virus (HCV) is a positive-strand RNA virus within the Flaviviridae family. The viral "spike" of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediate viral entry by engaging host receptors and undergoing conformational changes to facilitate membrane fusion. While E2 can be readily produced in the absence of E1, E1 cannot be expressed without E2 and few reagents, including monoclonal antibodies (mAbs), are available for study of this essential HCV glycoprotein. A human mAb to E1, IGH526, was previously reported to cross-neutralize different HCV isolates, and therefore, we sought to further characterize the IGH526 neutralizing epitope to obtain information for vaccine design. We found that mAb IGH526 bound to a discontinuous epitope, but with a major component corresponding to E1 residues 314-324. The crystal structure of IGH526 Fab with this E1 glycopeptide at 1.75Å resolution revealed that the antibody binds to one face of an α-helical peptide. Single mutations on the helix substantially lowered IGH526 binding but did not affect neutralization, indicating either that multiple mutations are required or that additional regions are recognized by the antibody in the context of the membrane-associated envelope oligomer. Molecular dynamics simulations indicate that the free peptide is flexible in solution, suggesting that it requires stabilization for use as a candidate vaccine immunogen.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  E1 envelope glycoprotein; HCV; IGH526; vaccine design

Mesh:

Substances:

Year:  2015        PMID: 26135247      PMCID: PMC4523428          DOI: 10.1016/j.jmb.2015.06.012

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  56 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

Review 2.  Prospects for a vaccine against the hepatitis C virus.

Authors:  Michael Houghton; Sergio Abrignani
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

Review 3.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

4.  Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.

Authors:  A Marco; J I Esteban; C Solé; A da Silva; J Ortiz; M Roget; C Sarriera; N Teixidó; R A Guerrero; J A Caylà
Journal:  J Hepatol       Date:  2013-03-22       Impact factor: 25.083

5.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

Authors:  Sharon E Frey; Michael Houghton; Stephen Coates; Sergio Abrignani; David Chien; Domenico Rosa; Piero Pileri; Ranjit Ray; Adrian M Di Bisceglie; Paola Rinella; Heather Hill; Mark C Wolff; Viola Schultze; Jang H Han; Bruce Scharschmidt; Robert B Belshe
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Structural characterization of the transmembrane proximal region of the hepatitis C virus E1 glycoprotein.

Authors:  Roberta Spadaccini; Gerardino D'Errico; Viviana D'Alessio; Eugenio Notomista; Alessia Bianchi; Marcello Merola; Delia Picone
Journal:  Biochim Biophys Acta       Date:  2009-11-03

9.  A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

Authors:  John Lok Man Law; Chao Chen; Jason Wong; Darren Hockman; Deanna M Santer; Sharon E Frey; Robert B Belshe; Takaji Wakita; Jens Bukh; Christopher T Jones; Charles M Rice; Sergio Abrignani; D Lorne Tyrrell; Michael Houghton
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  26 in total

1.  Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Authors:  Rehab I Moustafa; Juliano G Haddad; Lydia Linna; Xavier Hanoulle; Véronique Descamps; Ahmed Atef Mesalam; Thomas F Baumert; Gilles Duverlie; Philip Meuleman; Jean Dubuisson; Muriel Lavie
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

2.  Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Authors:  Ahmed Atef Mesalam; Isabelle Desombere; Ali Farhoudi; Freya Van Houtte; Lieven Verhoye; Jonathan Ball; Jean Dubuisson; Steven K H Foung; Arvind H Patel; Mats A A Persson; Geert Leroux-Roels; Philip Meuleman
Journal:  Virology       Date:  2017-11-10       Impact factor: 3.616

3.  Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.

Authors:  Brian G Pierce; Elisabeth N Boucher; Kurt H Piepenbrink; Monir Ejemel; Chelsea A Rapp; William D Thomas; Eric J Sundberg; Zhiping Weng; Yang Wang
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

4.  Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.

Authors:  Juliano G Haddad; Yves Rouillé; Xavier Hanoulle; Véronique Descamps; Monzer Hamze; Fouad Dabboussi; Thomas F Baumert; Gilles Duverlie; Muriel Lavie; Jean Dubuisson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.

Authors:  Michelle D Colbert; Andrew I Flyak; Clinton O Ogega; Valerie J Kinchen; Guido Massaccesi; Mayda Hernandez; Edgar Davidson; Benjamin J Doranz; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 6.  Viral evasion and challenges of hepatitis C virus vaccine development.

Authors:  Brian G Pierce; Zhen-Yong Keck; Steven Kh Foung
Journal:  Curr Opin Virol       Date:  2016-09-19       Impact factor: 7.090

Review 7.  Hepatitis C Virus Structure: Defined by What It Is Not.

Authors:  Altaira D Dearborn; Joseph Marcotrigiano
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 6.915

Review 8.  From Structural Studies to HCV Vaccine Design.

Authors:  Itai Yechezkel; Mansun Law; Netanel Tzarum
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.818

Review 9.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 10.  Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development.

Authors:  Eric A Toth; Andrezza Chagas; Brian G Pierce; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.